GST (Gefitinib as Salvage Treatment) in Pretreated Head and Neck Squamous Cell Cancer

Article Information

Faraz Khan, Manas Dubey*, Rajeev Atri, Vivek Kaushal, Rakesh Dhankhar, Anil Kr Dhull

Department of Radiation Oncology, Regional Cancer Centre, Pt. BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India

*Corresponding Author: Manas Dubey, Department of Radiation Oncology, Regional Cancer Centre, Pt. BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India

Received: 04 January 2019; Accepted: 16 January 2019; Published: 21 January 2019

Citation: Faraz Khan, Manas Dubey, Rajeev Atri, Vivek Kaushal, Rakesh Dhankhar, Anil Kr Dhull. GST (Gefitinib as Salvage Treatment) in Pretreated Head and Neck Squamous Cell Cancer. Journal of Cancer Science and Clinical Therapeutics 3 (2019): 1-4.

Share at Facebook

Abstract

Purpose: To determine the efficacy and safety profiles of GST (gefitinib as salavage therapy) in patients with advanced recurrent, residual and/or metastatic squamous cell cancer of the head and neck (HNSCC).

Subjects and Methods: Patients with recurrent, residual, or metastatic (R/R/M) HNSCC, were treated with gefitinib 250mg orally daily for 3 weeks.

Results and Conclusion: Partial response (PR) was noted in 10% of patients, median progression free survival (PFS) was 3.3 months. Anemia was observed in 16.7% of patients, toxicity related to total leucocyte count grade I,II &III toxicities were observed in 20%, 3.3% and 0%. Only grade I hepatic toxicity was observed in 20%. No case of renal toxicity was seen. Grade I-II upper gastrointestinal toxicity (nausea/ vomiting) was noted in 13.3% patients. Lower gastrointestinal toxicity (diarrhea) was observed in 46.7% of patients. Skin rash was graded and 8 (26.7%) patients demonstrated skin reactions. Overall survival (OS) was 4 months. Gefitinib was well tolerated in this heavily pretreated HNSCC population and produced prolonged disease stabilization.

Keywords

Gefitinib, Palliative, Head and neck cancer, Chemoradiation

Gefitinib articles Gefitinib Research articles Gefitinib review articles Gefitinib PubMed articles Gefitinib PubMed Central articles Gefitinib 2023 articles Gefitinib 2024 articles Gefitinib Scopus articles Gefitinib impact factor journals Gefitinib Scopus journals Gefitinib PubMed journals Gefitinib medical journals Gefitinib free journals Gefitinib best journals Gefitinib top journals Gefitinib free medical journals Gefitinib famous journals Gefitinib Google Scholar indexed journals Palliative articles Palliative Research articles Palliative review articles Palliative PubMed articles Palliative PubMed Central articles Palliative 2023 articles Palliative 2024 articles Palliative Scopus articles Palliative impact factor journals Palliative Scopus journals Palliative PubMed journals Palliative medical journals Palliative free journals Palliative best journals Palliative top journals Palliative free medical journals Palliative famous journals Palliative Google Scholar indexed journals Head and neck cancer articles Head and neck cancer Research articles Head and neck cancer review articles Head and neck cancer PubMed articles Head and neck cancer PubMed Central articles Head and neck cancer 2023 articles Head and neck cancer 2024 articles Head and neck cancer Scopus articles Head and neck cancer impact factor journals Head and neck cancer Scopus journals Head and neck cancer PubMed journals Head and neck cancer medical journals Head and neck cancer free journals Head and neck cancer best journals Head and neck cancer top journals Head and neck cancer free medical journals Head and neck cancer famous journals Head and neck cancer Google Scholar indexed journals Chemoradiation articles Chemoradiation Research articles Chemoradiation review articles Chemoradiation PubMed articles Chemoradiation PubMed Central articles Chemoradiation 2023 articles Chemoradiation 2024 articles Chemoradiation Scopus articles Chemoradiation impact factor journals Chemoradiation Scopus journals Chemoradiation PubMed journals Chemoradiation medical journals Chemoradiation free journals Chemoradiation best journals Chemoradiation top journals Chemoradiation free medical journals Chemoradiation famous journals Chemoradiation Google Scholar indexed journals metastatic squamous cell cancer articles metastatic squamous cell cancer Research articles metastatic squamous cell cancer review articles metastatic squamous cell cancer PubMed articles metastatic squamous cell cancer PubMed Central articles metastatic squamous cell cancer 2023 articles metastatic squamous cell cancer 2024 articles metastatic squamous cell cancer Scopus articles metastatic squamous cell cancer impact factor journals metastatic squamous cell cancer Scopus journals metastatic squamous cell cancer PubMed journals metastatic squamous cell cancer medical journals metastatic squamous cell cancer free journals metastatic squamous cell cancer best journals metastatic squamous cell cancer top journals metastatic squamous cell cancer free medical journals metastatic squamous cell cancer famous journals metastatic squamous cell cancer Google Scholar indexed journals gastrointestinal toxicity articles gastrointestinal toxicity Research articles gastrointestinal toxicity review articles gastrointestinal toxicity PubMed articles gastrointestinal toxicity PubMed Central articles gastrointestinal toxicity 2023 articles gastrointestinal toxicity 2024 articles gastrointestinal toxicity Scopus articles gastrointestinal toxicity impact factor journals gastrointestinal toxicity Scopus journals gastrointestinal toxicity PubMed journals gastrointestinal toxicity medical journals gastrointestinal toxicity free journals gastrointestinal toxicity best journals gastrointestinal toxicity top journals gastrointestinal toxicity free medical journals gastrointestinal toxicity famous journals gastrointestinal toxicity Google Scholar indexed journals carcinoma articles carcinoma Research articles carcinoma review articles carcinoma PubMed articles carcinoma PubMed Central articles carcinoma 2023 articles carcinoma 2024 articles carcinoma Scopus articles carcinoma impact factor journals carcinoma Scopus journals carcinoma PubMed journals carcinoma medical journals carcinoma free journals carcinoma best journals carcinoma top journals carcinoma free medical journals carcinoma famous journals carcinoma Google Scholar indexed journals malignancies articles malignancies Research articles malignancies review articles malignancies PubMed articles malignancies PubMed Central articles malignancies 2023 articles malignancies 2024 articles malignancies Scopus articles malignancies impact factor journals malignancies Scopus journals malignancies PubMed journals malignancies medical journals malignancies free journals malignancies best journals malignancies top journals malignancies free medical journals malignancies famous journals malignancies Google Scholar indexed journals gefitinib as salvage therapy articles gefitinib as salvage therapy Research articles gefitinib as salvage therapy review articles gefitinib as salvage therapy PubMed articles gefitinib as salvage therapy PubMed Central articles gefitinib as salvage therapy 2023 articles gefitinib as salvage therapy 2024 articles gefitinib as salvage therapy Scopus articles gefitinib as salvage therapy impact factor journals gefitinib as salvage therapy Scopus journals gefitinib as salvage therapy PubMed journals gefitinib as salvage therapy medical journals gefitinib as salvage therapy free journals gefitinib as salvage therapy best journals gefitinib as salvage therapy top journals gefitinib as salvage therapy free medical journals gefitinib as salvage therapy famous journals gefitinib as salvage therapy Google Scholar indexed journals Tumor assessment articles Tumor assessment Research articles Tumor assessment review articles Tumor assessment PubMed articles Tumor assessment PubMed Central articles Tumor assessment 2023 articles Tumor assessment 2024 articles Tumor assessment Scopus articles Tumor assessment impact factor journals Tumor assessment Scopus journals Tumor assessment PubMed journals Tumor assessment medical journals Tumor assessment free journals Tumor assessment best journals Tumor assessment top journals Tumor assessment free medical journals Tumor assessment famous journals Tumor assessment Google Scholar indexed journals

Article Details

1. Introduction

Worldwide incidence carcinoma of head and neck region in 2012 were 599,637 which was 4.2% of all cancers. Deaths due to carcinoma of head and neck were 324,834 which was 4% of all cancers [1]. In India alone, 2.5 lakhs new patients are diagnosed every year, of whom about 70% are in an locally advanced stage [2]. Carcinoma of head and neck is one of the commonest malignancies in India and is responsible for 22.9% of cancer related mortality [3]. Approximately 70-80% of these patients are diagnosed with locally advanced disease [4]. Chemoradiation is most preferrable treatment for LAHNC [5, 6]. Local failure rate is high in the range of 60-70%. These patients carry limited prognosis and are suitable for palliative treatment. Palliative treatment is based on many considerations such as borderline performance status (PS), existing co-morbidities, etc [7]. Combination chemotherapy is more effective than single agent chemotherapy but is sometimes not tolerated by patients because of poor nutritional status and general condition of the patients. In view of above, we enrolled thirty patients in this study and they received gefitinib as salvage therapy (GST) in HNSCC.

2. Material and Methods

Thirty Patients with histologically or cytologically proven diagnosis of locally R/R/M HNSCC from any of the primary sites were candidates for this study who were pretreated (had surgery and/or radiation therapy with/without concomitant chemotherapy). Patients were enrolled for the study after obtaining informed written consent. All patients received Gefitinib 250 mg daily for 3 weeks. Tumor assessment was done by consistent clinical examination after 3 weeks of starting therapy and commencement of next cycles for 6 cycles.

3. Results

Partial response (PR) was noted in 10% of patients, median progression free survival (PFS) was 3.3 months. Anemia was observed in 16.7% of patients, toxicity related to total leucocyte count grade I,II &III toxicities were observed in 20%, 3.3% and 0%. Only grade I liver toxicity was found in 20%. No case of renal toxicity was seen. Grade I-II upper gastrointestinal toxicity (nausea/ vomiting) was noted in 13.3% patients. Lower gastrointestinal toxicity (diarrhea) was observed in 46.7% of patients. Skin rash was graded and 8 (26.7%) patients demonstrated skin reactions. Overall survival (OS) was 4 months.

4. Discussion and Conclusion

Epidermal growth factor receptor (EGFR) , is a transmembrane glycoprotein whose intracellular domain has tyrosine kinase activity. EGFR is involved in in the regulation of cell cycle progression, inhibition of apoptosis, angiogenesis, tumor cell invasion and metastasis. Gefitinib is an inhibitor of tyrosine kinase that blocks the pathway of signal transduction [8]. EGFR is overexpressed in 85% to 95% HNSCC [8]. Gefitinib in a dose dependent manner has been shown to disrupt cell cycle progression [9].

Baselga et al studied Gefitinib in 28 patients with HNSCC (Total no. of patients=250). Gefitinib in the range 150-800 mg was was favorably tolerated. The most common toxicities reported were diarrhea (47-55%), asthenia (44%) and acnieform follicular rash (46-64%). Stable disease was achieved in 50% of patients HNSCC [10]. In a phase 2 study by Cohen et al, evaluated oral Gefitinib (500 mg /day) in 52 patients with R/R/M HNSCC. The objective PR rate of 10.6% was seen. 3.4 and 8.1 months were the median time to progression and death and an estimated 1 year survival of 29%. Only a single case of grade 4 toxicity (hypercalcemia), a 4-6% of grade 3 toxicity (anorexia, diarrhea, nausea), 48% patients developed grade 1 or 2 cutaneous rash [11].

Athnassios et al randomly assigned patients with R/R/M SCCHN to receive weekly Docetaxel plus either placebo (arm A) OR Gefitinib 250mg/day orally (arm B) until disease progression. The study was closed early after 270 patients were enrolled and an interim analysis was done (arm A, n=136, arm B, n=134). Median OS was 6 months in arm A vs 7 months in arm B, further careful analysis showed that Gefitinib improved survival in patients lessr than 65 years old [12].

Belon et al have investigated Gefitinib together with Docetaxel based regimens for the treatment of SCCHN. The addition of Gefitinib to the well established taxanes and platinum regimen was investigated in phase 2 trial in 23 patients with recurrent residual and metastatic SCCHN. In this trial, the half of the patients shown PFS of 5.1 months. Safety analysis demonstarted as, grade 3/4 toxicities including neutropenia (41.2% of patients, including 23.5% with febrile neutropenia), anemia (17.7%), asthenia (11.8%) and diarrhea, vomiting, anorexia, and leucopenia (5.9% each) [13].

Vermorken et al. conducted a randomized phase III trial large number of (n=482) patients with R/R/M-SCCHN, refractory to platinum or not suitable for platinum based therapy, were divided in 3 groups to receive either tablet Gefitinib 250 mg/day or 500 mg/day or t methotrexate 40 mg/m2 i.v. weekly. Neither Gefitinib 250 mg/day nor Gefitinib 500 mg/day has shown benefit in survival in relation with i.v methotrexate. Overall Response rates were 2.7%, 7.6% and 3.9%, respectively and median OS was 5.6, 6 and 6.7 months, respectively [14]. In our study gefitinib was favorably accepted and had fewer systemic effects and it can be warranted that GST has a potential role in pretreated HNSCC.

References

  1. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015): E359-386.
  2. Sharma M, Madan M, Manjari M, et al. Prevalence of Head and Neck Squamous Cell Carcinoma (HNSCC) in our population: The clinic-pathological and morphological description of 198 cases. International Journal of Advanced Research 1 (2015): 827-833.
  3. Dikshit R, Gupta PC, Ramasundarahettige C, et al. Cancer mortality in India: a nationally representative survey. Lancet 379 (2012): 1807-1816.
  4. Stupp R, Weichselbaum RR, Vokes EE. Combined modality therapy of head and neck cancer. SeminOncol 21 (1994): 349-358.
  5. Perez CA, Carmichael T, Devineni VR. Carcinoma of the tonsillar fossa: A nonrandomized comparison of irradiation alone or combined with surgery: Long-term results. Head Neck 13 (1991): 282-290.
  6. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J ClinOncol 29 (2006): 290-297.
  7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers.v.2-2017. Fort Washington, Pennsylvania: National Comprehensive Cancer Network (2017).
  8. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and P21CIP1/WAF1 in the Antiproliferative effect of ZD1839(“IRESSA”), an epidermal growth factor Tyrosine Kinase inhibitor, in head and neck squamous carcinoma cells.J cell Physiol 195 (2003): 139-150.
  9. Di Gennaro E, Barbarino M, Bruzzesse F, et al. Role of Gefitinib in Angiogenesis.J Physiol 210 (2003): 130-152.
  10. Baselga J, Rischin D, Ranson M, et al. Phase 1 safety, pharmacokinetic and pharmacodynamic trial of ZD 1839, A selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumour types. J Clin Oncol 20 (2002): 4292-4302.
  11. Cohen EEW, Stenson K, Gustin DM, et al. A phase II study of 250 mg Gefitinib(ZD 1839) monotherapy in recurrent or metastatic squamous cell carcinoma of head and neck. J Clin Oncol 22 (2003): 502.
  12. Athanassios A, Ghebremichael M, Gilbert J, et al. Phase 3 randomize, placebo controlled trial of Docetaxel with or without Gefitinib in recurrent or metastatic head and neck cancer.An eastern cooperative oncology group trial. J Clin Oncol 31 (2013): 1405-1414.
  13. Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase 2 study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of head and neck. J Clin Oncol 23 (2005): 22-23.
  14. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Annals of oncology 21 (2010): vii252-vii261.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved